Sessions explore treatment advances and multidisciplinary care
As new therapies and modalities are emerging for treating head and neck cancers, Cleveland Clinic Cancer Center is hosting an in-person CME program highlighting:
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“The course will highlight innovative approaches to head and neck cancer treatment,” says Joseph Scharpf, MD, Director of Head and Neck Endocrine Surgery at Cleveland Clinic. “It will provide an excellent contemporary update and highlight cutting-edge treatments, which have evolved in all the specialties represented.”
The program, entitled 2023 Contemporary Multidisciplinary Care of the Head and Neck Cancer Patient: Updates on the Innovative Approaches to Head and Neck Cancer Treatment, will be held on Friday, November 17, 2023 at Cleveland Clinic Learner Research Institute. The sessions are recommended for head and neck surgeons, otolaryngologists, medical oncologists, radiation oncologists, trainees, advanced practice providers as well as speech language pathologists and nurses involved in the diagnosis and treatment of head and neck cancers.
Specialists from head and neck oncology, head and neck endocrine surgery, radiation oncology, medical oncology, speech and language pathology, oral rehabilitation surgery, dermatologic surgery, radiology, pathology and reconstructive surgery will lead the sessions. “The panels include expert faculty drawing from leaders in our field internally at Cleveland Clinic and nationally recognized guests, including an alumnus as a guest of honor,” says Dr. Scharpf.
Sessions will cover:
Advertisement
This live activity represents a maximum of 7.50 AM PRA category 1 credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for category 2 credit. A certificate of participation will be provided to other health care professionals for requesting credit in accordance with their professional boards and/or associations.
$150 for physicians
$50 for allied health professionals, residents and fellows
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust
FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer